Inhibikase Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.09 | $-0.11 | -22.2% | Miss |
| Q12026 FY2026 | $-0.10 | $-0.10 | +0.0% | Beat |
| Q42025 FY2025 | $-0.12 | $-0.09 | +25.0% | Beat |
Back to IKT overview · IKT holders · IKT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.